Meta Pixel

News and Announcements

Another solid performance from the TAIM Funds in July

  • Published August 07, 2019 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Global share markets continued to be buoyed during July by confirmation that central banks will maintain their “lower for longer” approach to interest rates. After two and a half years sitting on the sidelines, our Reserve Bank has now cut rates two months in a row. While this focus on interest rates has translated into a positive response on the share market, forecasts for global growth in the coming years continue to be tested.

TAIM’s Funds have continued their consistent outperformance of the general market during July. Our principle Momentum Fund has now outperformed its benchmark, the ASX200 Accumulation Index, by a very healthy 20% plus in the 22 months since its inception.

Our Leveraged Fund continues its stellar run in 2019, with its second straight month with a greater than +10% gain. This Fund has returned over 78% for investors this calendar year and has more than doubled the performance of its benchmark since inception.

The Australian ASX200 finally broke through its previous high, after almost 12 years, at the end of the month, before retreating. With trade tensions testing global markets, and the August company reporting season in full swing back home, our market may be more volatile in the coming weeks.

 

About TAIM Investments

TAIM Investments operates two Australian equities investment funds. Both have exhibited exceptional performance, during an initial 4-year small-scale-offering period, and now under the company’s own AFSL. Both funds have an Australian blue chip focus – portfolio of 20 ASX200 equities, long only, no short-selling or derivatives – and we use an automated quantitative approach to deliver superior performance.

Register Interest

Capital Insights
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship

From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now